Literature DB >> 20504946

Do point prevalence and prolonged abstinence measures produce similar results in smoking cessation studies? A systematic review.

John R Hughes1, Matthew J Carpenter, Shelly Naud.   

Abstract

INTRODUCTION: Many smoking cessation trials report either prolonged abstinence (PA) rates (i.e., not smoking since a quit date, with or without a grace period) or point prevalence (PP) abstinence rates (i.e., no smoking one or more days prior to the follow-up), but how these two relate is unclear.
METHODS: We located 28 pharmacotherapy trials that provided 76 within-study comparisons of PA versus PP. The first two authors independently coded all trials.
RESULTS: The two measures were highly correlated (r = .88) and PA averaged 0.74 that of PP. Equations for converting PP to PA and vice versa produced estimations that, in 90% of cases, were within 4%-5% of actual PP or PA values. The odds ratio and the relative risk for active versus control were identical when PA and PP were used; however, the difference in proportion abstinent for active versus control was somewhat less when PA was used than when PP was used (8% vs. 10%). DISCUSSION: We conclude that PA and PP are closely related and can be interconverted with moderate accuracy. They also produce similar effect sizes when odds ratio and relative risk are used as effect sizes. When absolute difference in percent abstinent is used as an effect size, PA produces a smaller effect size than PP. We believe trials should continue to report both PA and PP outcomes to enhance comparisons across studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20504946      PMCID: PMC2893294          DOI: 10.1093/ntr/ntq078

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  51 in total

1.  Methodological issues in measuring treatment outcome in adolescent smoking cessation studies.

Authors:  Robin Mermelstein; Suzanne M Colby; Christi Patten; Alexander Prokhorov; Richard Brown; Mark Myers; William Adelman; Karen Hudmon; Paul McDonald
Journal:  Nicotine Tob Res       Date:  2002-11       Impact factor: 4.244

2.  Outcome criteria in smoking cessation trials: proposal for a common standard.

Authors:  Robert West; Peter Hajek; Lindsay Stead; John Stapleton
Journal:  Addiction       Date:  2005-03       Impact factor: 6.526

3.  Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers.

Authors:  Saul Shiffman; Deborah M Scharf; William G Shadel; Chad J Gwaltney; Qianyu Dang; Stephanie M Paton; Duncan B Clark
Journal:  J Consult Clin Psychol       Date:  2006-04

4.  Errors in interpreting abstinence curves in studies of smoking cessation.

Authors:  John R Hughes; Peter W Callas
Journal:  Nicotine Tob Res       Date:  2006-02       Impact factor: 4.244

5.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

6.  The transdermal nicotine patch: results of a randomised placebo-controlled trial.

Authors:  R L Richmond; K Harris; A de Almeida Neto
Journal:  Med J Aust       Date:  1994-07-18       Impact factor: 7.738

7.  Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.

Authors:  H J Aubin; F Lebargy; I Berlin; C Bidaut-Mazel; J Chemali-Hudry; G Lagrue
Journal:  Addiction       Date:  2004-09       Impact factor: 6.526

8.  Measures of abstinence in clinical trials: issues and recommendations.

Authors:  John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan
Journal:  Nicotine Tob Res       Date:  2003-02       Impact factor: 4.244

9.  A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling.

Authors:  Danielle E McCarthy; Thomas M Piasecki; Daniel L Lawrence; Douglas E Jorenby; Saul Shiffman; Michael C Fiore; Timothy B Baker
Journal:  Nicotine Tob Res       Date:  2008-04       Impact factor: 4.244

10.  Smoking cessation in women concerned about weight.

Authors:  P L Pirie; C M McBride; W Hellerstedt; R W Jeffery; D Hatsukami; S Allen; H Lando
Journal:  Am J Public Health       Date:  1992-09       Impact factor: 9.308

View more
  39 in total

1.  Understanding quit patterns from a randomized clinical trial: Latent classes, predictors, and long-term abstinence.

Authors:  Lorra Garey; Kara Manning; Danielle E McCarthy; Matthew W Gallagher; Justin M Shepherd; Michael F Orr; Norman B Schmidt; Blaz Rodic; Michael J Zvolensky
Journal:  Addict Behav       Date:  2019-02-21       Impact factor: 3.913

2.  A pilot randomized controlled trial of smoking cessation in an outpatient respirology clinic.

Authors:  Smita Pakhale; Justine Baron; Michael A Armstrong; Avanti Garde; Robert D Reid; Gonzalo Alvarez; Debbie Aitken; Kerri-Anne Mullen; George Wells; Andrew Pipe
Journal:  Can Respir J       Date:  2015-02-03       Impact factor: 2.409

3.  Markov model of smoking cessation.

Authors:  Peter R Killeen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-20       Impact factor: 11.205

4.  Evaluation of health promotion programmes in severe mental illness: theory and practice.

Authors:  Fenneke M van Hasselt; Paul F M Krabbe; Maarten J Postma; Anton J M Loonen
Journal:  Int J Methods Psychiatr Res       Date:  2014-12-09       Impact factor: 4.035

5.  Tobacco use among adults initiating treatment for HIV infection in rural Uganda.

Authors:  Gina R Kruse; David R Bangsberg; Judith A Hahn; Jessica E Haberer; Peter W Hunt; Conrad Muzoora; John P Bennett; Jeffrey N Martin; Nancy A Rigotti
Journal:  AIDS Behav       Date:  2014-07

6.  The Positive Emotions after Acute Coronary Events behavioral health intervention: Design, rationale, and preliminary feasibility of a factorial design study.

Authors:  Jeffery C Huffman; Ariana M Albanese; Kirsti A Campbell; Christopher M Celano; Rachel A Millstein; Carol A Mastromauro; Brian C Healy; Wei-Jean Chung; James L Januzzi; Linda M Collins; Elyse R Park
Journal:  Clin Trials       Date:  2017-01-12       Impact factor: 2.486

Review 7.  Metabotropic glutamate receptor 5 as a potential target for smoking cessation.

Authors:  Cristiano Chiamulera; Claudio Marcello Marzo; David J K Balfour
Journal:  Psychopharmacology (Berl)       Date:  2016-11-16       Impact factor: 4.530

Review 8.  Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes.

Authors:  Kathleen M Carroll; Brian D Kiluk; Charla Nich; Elise E DeVito; Suzanne Decker; Donna LaPaglia; Dianne Duffey; Theresa A Babuscio; Samuel A Ball
Journal:  Drug Alcohol Depend       Date:  2014-01-31       Impact factor: 4.492

9.  Planning a Change Easily (PACE): A randomized controlled trial for smokers who are not ready to quit.

Authors:  Francisco I Salgado García; Karen J Derefinko; Zoran Bursac; Sarah Hand; Robert C Klesges
Journal:  Contemp Clin Trials       Date:  2018-03-13       Impact factor: 2.226

10.  Marijuana and alcohol use and attempted smoking cessation in adolescent boys and girls.

Authors:  Deepa R Camenga; Grace Kong; Kara Bagot; Rani A Hoff; Marc N Potenza; Suchitra Krishnan-Sarin
Journal:  Subst Abus       Date:  2014       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.